Apogee Therapeutics APGE 深 沪
交易中 12-16 10:21:35 美东时间
77.21
+0.400
+0.52%
华盛通- 最 高77.21
- 今 开75.40
- 成交量 1.20万股
- 最 低 74.52
- 昨 收 76.81
- 总市值 51.38亿
- 52周最高 78.15
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 26.20
- 委 比 73.26%
- 总股本 6654.76万
- 历史最高 78.15
- 量 比 0.13
- 振 幅 3.50%
- 历史最低 14.19
- 每 手 1
- 风险率 10.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Deutsche Bank Initiates Coverage On Apogee Therapeutics with Buy Rating, Announces Price Target of $103
Deutsche Bank analyst David Hoang initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $103.
12-10 19:53
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
Turn Therapeutics' GX-03 technology, targeting IL-36 and IL-31, has been recognized by *Patient Care Online* as a top innovation for atopic dermatitis treatment. This topical agent offers a novel mechanism addressing inflammation behind eczema and psoriasis, potentially reducing reliance on systemics and injectables. The company expects to release lead program data for severe eczema in early 2026. Turn Therapeutics also focuses on advancing wound...
11-11 13:00
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
RBC Capital Maintains Outperform on Apogee Therapeutics, Raises Price Target to $70
RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Outperform and raises the price target from $60 to $70.
11-03 22:37
Apogee Therapeutics to Participate in Upcoming Conferences
Apogee Therapeutics announced that its management team will participate in several investor conferences from November 11 to December 3, 2025, including Guggenheim, Stifel, TD Cowen, Jefferies, and Citi conferences. The company is a clinical-stage biotech advancing novel biologics for large immune-inflammatory markets, such as Atopic Dermatitis, asthma, and COPD, with APG777 as its lead program targeting Atopic Dermatitis. Fireside chats will be a...
11-03 12:30
Mizuho Securities Keeps Their Buy Rating on Apogee Therapeutics (APGE)
In a report released on October 27, Joseph Catanzaro from Mizuho Securities mai...
10-29 17:56
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
Mizuho Initiates Coverage On Apogee Therapeutics with Outperform Rating, Announces Price Target of $105
Mizuho analyst Joseph Catanzaro initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Outperform rating and announces Price Target of $105.
10-21 20:42
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million
Apogee Therapeutics完成8,048,782股普通股的公开募股，每股41美元，总募股额约3.45亿美元。此外，提供365,853股预资助认股权证，总价值约1480万美元，总募资约3.45亿美元。公司专注于炎症和免疫学市场的生物制剂开发，旨在最佳治疗如湿疹、哮喘等疾病。
10-10 20:01
